Science AI Journal
Medicine · Research topic

Open research questions in Cancer Treatment and Pharmacology

96 unresolved questions extracted from the limitations and future-work sections of 377 Cancer Treatment and Pharmacology papers in our library. Each links back to the study that raised it.

What the literature leaves open

  • Investigation of NCX2 as a potential preventive target for OIPN, - Direct validation of reverse-mode NCX activity, Na+/Ca2+ fluxes, NCX2 directionality, and translational relevance, - Elucidation of the cellular and molecular mechanisms linking acute axonal hyperexcitability to later structural degeneration

    NCX2 Targeting as a Neuroprotective Strategy Against Oxaliplatin-Induced Peripheral Neurotoxicity · 2026 · DOI

  • The mechanisms that link acute axonal hyperexcitability to later structural degeneration are not well understood. There is a need for preventive strategies for OIPN. The present findings do not directly demonstrate reverse-mode NCX2 activity or establish a temporal transition from acute hyperexcitability to chronic degeneration.

    NCX2 Targeting as a Neuroprotective Strategy Against Oxaliplatin-Induced Peripheral Neurotoxicity · 2026 · DOI

  • Investigation of eribulin's adverse events in different patient populations, - Analysis of eribulin's synergy with tumor immunotherapy, - Development of new treatments using eribulin as a payload in an antibody-drug conjugate

    Safety of eribulin: A real-world study based on a pharmacovigilance database · 2026 · DOI

  • The lack of comprehensive analysis of eribulin's adverse event profile - The need for a thorough investigation of eribulin's adverse events - The importance of understanding eribulin's safety profile to guide clinical use

    Safety of eribulin: A real-world study based on a pharmacovigilance database · 2026 · DOI

  • Further research is needed to confirm the results and to explore the potential benefits and risks of CBD/CBG exposure in patients receiving neurotoxic chemotherapy, - Studies should investigate the optimal dosage and duration of CBD/CBG exposure for the prevention and treatment of CIPN, - Research should explore the potential mechanisms by which CBD/CBG exposure may reduce the risk of neuropathy-related diagnoses, - The effects of CBD/CBG exposure on quality of life and cancer outcomes should be investigated

    Cannabidiol/cannabigerol exposure and neuropathy-related outcomes after neurotoxic chemotherapy: a real-world cohort study · 2026 · DOI

  • There is a lack of effective pharmacologic options for prevention and treatment of established painful CIPN. The real-world clinical relevance of cannabidiol/cannabigerol exposure in patients receiving neurotoxic chemotherapy is unclear.

    Cannabidiol/cannabigerol exposure and neuropathy-related outcomes after neurotoxic chemotherapy: a real-world cohort study · 2026 · DOI

  • there is a high demand for better understanding of the cellular and molecular mechanisms involved in CIPN, - the development of new biomarkers and therapeutic targets is needed, - further studies on the correlation between single-nucleotide polymorphisms (SNPs) and the predisposition to CIPN are required

    Molecular and Cellular Involvement in CIPN · 2024 · DOI

  • The precise immunological pathways targeted by chemotherapy remain elusive. The results of studies on the correlation between single-nucleotide polymorphisms (SNPs) and the predisposition to CIPN have not consistently demonstrated uniform reproducibility.

    Molecular and Cellular Involvement in CIPN · 2024 · DOI

  • Despite its high prevalence, reliable methods for predicting CIPN remain insufficiently developed.

    Clinical and laboratory status of breast cancer patients with chemotherapy-induced polyneuropathy: a pilot study · 2026 · DOI

  • While oxaliplatin-induced peripheral neurotoxicity is well studied, its impact on CNS signaling remains poorly understood.

    Investigating the Effect of Oxaliplatin on Vesicular Dopamine Cargo and Release Dynamics in Brain with Single-Vesicle Electrochemistry · 2026 · DOI

  • To date, no studies have revealed that the elicitors derived from Fusarium graminearum enhance 10-deacetylbaccatin III (10-DABIII) and paclitaxel production in T.

    The effects of Fusarium graminearum cell extracts and culture filtrates on the production of paclitaxel and 10-deacetylbaccatin III in suspension cell cultures of Taxus baccata L. · 2025 · DOI

  • However, the molecular mechanisms governing SA-induced modulation of paclitaxel biosynthesis remain poorly elucidated.

    TcMYB73, a salicylic acid-responsive R2R3-MYB transcription factor, positively regulates paclitaxel biosynthesis in Taxus chinensis in direct and indirect ways · 2025 · DOI

  • However, the defining the distribution boundaries and mechanisms driving lineage differentiation of Taxus species in northern and central China remain unclear.

    Taxonomic status and spatial genetic pattern of Taxus in northern and central China: insights from integrative taxonomy, ecology and phylogeography · 2025 · DOI

  • Conclusion: CIPN is a common and understudied toxicity, despite being a limiting factor in the quality of life of many patients.

    NeuroPredict: study of the predictive value of ABCB1 genetic polymorphisms and associated clinical factors in chronic chemotherapy-induced peripheral neuropathy (CIPN) · 2024 · DOI

  • Studies have shown a possible association between the presence of genetic polymorphisms in ABCB1 and the development of acute CIPN, although this relationship with chronic CIPN remains unexplored.

    NeuroPredict: study of the predictive value of ABCB1 genetic polymorphisms and associated clinical factors in chronic chemotherapy-induced peripheral neuropathy (CIPN) · 2024 · DOI

  • remains controversial due to its continuous phenotypic variation and unstable topology, thus adversely affecting the formulation of scientific conservation strategies for this genus.

    Identification and characterization of a new species of Taxus — Taxus qinlingensis by multiple taxonomic methods · 2024 · DOI

  • Therefore, further investigation of eribulin-based treatment in larger randomized trials for patients with advanced TNBC is warranted.

    Feasibility and tolerability of eribulin-based chemotherapy versus other chemotherapy regimens for patients with metastatic triple-negative breast cancer: a single-centre retrospective study · 2024 · DOI

  • However there remains a gap in understanding the characteristics of VIPN in adults.

    Characterising vincristine-induced peripheral neuropathy in adults: symptom development and long-term persistent outcomes · 2024 · DOI

  • However, to date, there are no studies on high tone therapy in patients with chemotherapy-induced peripheral neuropathy.

    Home-based high tone therapy may alleviate chemotherapy-induced neuropathic symptoms in patients with colorectal cancer: A randomized double-blind placebo-controlled pilot evaluation · 2024 · DOI

  • Future research should focus on identifying neuroprotective measures to avoid an irreversible decline in the quality of life for breast cancer survivors.

    Early taxane exposure and neurotoxicity in breast cancer patients · 2024 · DOI

  • While useful preventive measures and predictors are lacking, patient education (e.

    A qualitative evaluation of the oncologists’, neurologists’, and pain specialists’ views on the management and care of chemotherapy-induced peripheral neuropathy in The Netherlands · 2024 · DOI

  • Despite recent international guidelines, a gold standard for diagnosis, treatment, and care is lacking.

    A qualitative evaluation of the oncologists’, neurologists’, and pain specialists’ views on the management and care of chemotherapy-induced peripheral neuropathy in The Netherlands · 2024 · DOI

  • Central morphological alterations in chemotherapy-induced neurotoxicity remain insufficiently investigated. The effects of paclitaxel-induced neurotoxicity on the cerebellum are not well understood.

    MORPHOLOGICAL CHANGES IN THE RAT CEREBELLUM AFTER PACLITAXEL-INDUCED NEUROTOXICITY AND THERAPEUTIC VORTIOXETINE TREATMENT · 2026 · DOI

  • The efficacy of cryotherapy in preventing CIPN is still uncertain, - The previous study's conclusion was not supported by the evidence

    Cooling the language on cryotherapy as an effective intervention to prevent or mitigate chemotherapy-induced peripheral neuropathy · 2026 · DOI

  • There is a need for effective maintenance therapies for HR+/HER2- MBC patients. The study aimed to address this gap by comparing fulvestrant with capecitabine in this patient population.

    Fulvestrant versus capecitabine as maintenance therapy in hormone receptor-positive, HER2-negative metastatic breast cancer after first-line chemotherapy (FAMILY): a multicenter, open-label, randomized, phase 3 trial · 2026 · DOI

Most-cited papers in Cancer Treatment and Pharmacology

Most recent work

Find a gap in your own Cancer Treatment and Pharmacology sub-topic

This page shows what the Cancer Treatment and Pharmacology literature already flags as unresolved. To narrow it to your specific question, search the Research Gap Finder: the search is free with a free account and lists the papers closest to your topic first. Unlocking that topic (50 credits, charged once) fills the comparison table from our 4.5M-paper local library and writes the gaps from its rows.

Open the Research Gap Finder →

Related topics in Medicine

Artificial Intelligence in Healthcare and Education
2,404 open questions
Substance Abuse Treatment and Outcomes
2,046 open questions
Dementia and Cognitive Impairment Research
1,148 open questions
Smoking Behavior and Cessation
1,056 open questions
Innovations in Medical Education
1,015 open questions
Physical Activity and Health
1,010 open questions
Attention Deficit Hyperactivity Disorder
970 open questions
Schizophrenia research and treatment
962 open questions
96 open questions have been extracted from the limitations and future-work passages of 377 Cancer Treatment and Pharmacology papers in our 4.5M-paper local library. Each one below links back to the study that raised it, so you can read the original claim in context.

Tools for your next paper

Gaps & Literature SearchFind open questions in any field — 120,000+ open gaps mined from our own library.Pre-CheckIs your paper ready? A Tier 1–5 acceptance probability in seconds.Journal FinderA ranked shortlist of target journals from a 17,500-venue index.Duplicate Publication CheckerCheck prior-publication & salami-slicing risk across 8 sources.Citation GeneratorFreeA DOI or title → APA, MLA, Vancouver, Chicago, BibTeX, RIS. No signup.Graphical Abstract MakerFreeTurn your findings into a colorblind-safe graphical abstract.

Compare the category — Honest roundups of the AI research tools, ours listed alongside the alternatives.

Command palette

Jump anywhere, run any action.